These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6028709)

  • 1. Melphalan in multiple myeloma.
    Hoogstraten B; Sheehe PR; Cuttner J; Cooper T; Kyle RA; Oberfield RA; Townsend SR; Harley JB; Hayes DM; Costa G; Holland JF
    Blood; 1967 Jul; 30(1):74-83. PubMed ID: 6028709
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.
    Rivers SL; Patno ME
    JAMA; 1969 Feb; 207(7):1328-34. PubMed ID: 4179565
    [No Abstract]   [Full Text] [Related]  

  • 3. Factors responsible for bone marrow toxicity after treatment of myeloma patients with different alkylating agents.
    Ringborg U; Lewensohn R
    Acta Med Scand; 1978; 203(4):276-8. PubMed ID: 645439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up and therapy in multiple myeloma.
    Vélez-García E; Maldonado N
    Cancer; 1971 Jan; 27(1):44-50. PubMed ID: 4099699
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple myeloma with coexistent myelofibrosis: improvement of myelofibrosis following recovery from multiple myeloma after treatment with melphalan and prednisolone.
    Kawauchi K; Mori H; Sugiyama H; Oshimi K; Hirayama A
    Jpn J Med; 1991; 30(5):483-6. PubMed ID: 1803051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of multiple myeloma.
    Brodsky I; Kahn SB; Meyer AN
    Geriatrics; 1967 Mar; 22(3):140-8. PubMed ID: 6019488
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of multiple myeloma with melphalan: 35 personal cases].
    Dryll A; Ryckewaert A; Kahn MF; Hayat M; de Seze S
    Sem Hop; 1970 Jan; 46(5):289-98. PubMed ID: 4327260
    [No Abstract]   [Full Text] [Related]  

  • 8. Intermittent melphalan therapy in multiple myeloma.
    Hoogstraten B; Costa J; Cuttner J; Forcier J; Leone LA; Harley JB; Glidewell OJ
    JAMA; 1969 Jul; 209(2):251-3. PubMed ID: 5819231
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of multiple myeloma.
    Waldenström J
    Br J Haematol; 1968 Sep; 15(3):217-20. PubMed ID: 5681477
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma.
    Caggiano V; Cuttner J; Solomon A
    Blood; 1967 Sep; 30(3):265-87. PubMed ID: 6038301
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple myeloma. II. The value of melphalan.
    Bernard DB; Lynch SR; Bothwell TH; Bezwoda WR; Stevens K; Shulman G
    S Afr Med J; 1974 May; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract]   [Full Text] [Related]  

  • 12. Melphalan therapy for plasma cell myeloma.
    Alexanian R; Bergsagel DE; Migliore PJ; Vaughn WK; Howe CD
    Blood; 1968 Jan; 31(1):1-10. PubMed ID: 5638562
    [No Abstract]   [Full Text] [Related]  

  • 13. [Comparative study of the melphalan and of the cyclophosphamide in the treatment of Kahler's disease].
    Bontoux D; Chenbit D; Delbarre F
    Therapeutique; 1971 Jan; 47(1):27-32. PubMed ID: 5572915
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of myeloma].
    Le Chevallier PL
    Sem Hop; 1971 Jan; 47(4):249-51. PubMed ID: 4322132
    [No Abstract]   [Full Text] [Related]  

  • 15. A urinary cryo-Bence Jones protein gelling at room temperature.
    Harris RI; Kohn J
    Clin Chim Acta; 1974 Jun; 53(2):233-7. PubMed ID: 4841989
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR; Kochwa S; Dosik H
    Cancer Treat Rep; 1982 Mar; 66(3):475-81. PubMed ID: 7060036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma. A clinical review.
    Rosen BJ
    Med Clin North Am; 1975 Mar; 59(2):375-86. PubMed ID: 1078867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
    McElwain TJ; Powles RL
    Lancet; 1983 Oct; 2(8354):822-4. PubMed ID: 6137651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma without initial paraproteins.
    Kim I; Harley JB; Weksler B
    Am J Med Sci; 1972 Oct; 264(4):267-75. PubMed ID: 4630526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.